women who developed APOs (Group 2¼APO group). APO was defined as the development of at least one of the followings: preeclampsia, fetal death in utero, neonatal death before hospital discharge, indicated preterm birth <36 weeks, and small for gestational age (<5th percentile) at birth. Stored samples of amniotic fluids were analyzed using mass spectrometry-based proteomics. In a discovery phase, we analyzed 9 patients (4 in Group 1 and 5 in Group 2) with data-dependent acquisition (DDA) approach. In a verification phase, we analyzed the remained 26 patients (15 in Group 1 and 11 in Group 2) using data-independent acquisition (DIA) method. Hierarchical clustering was performed based on the Euclidean distance and the average linkage. RESULTS: In the discovery phase, 44 proteins were differentially expressed between Group 1 and Group 2. In a verification phase, differentially expressed proteins (DEPs) were verified in independent samples using DIA method. Four proteins including FLNA (filamin A), SVEP1 (sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1), LCAT (lecithin-cholesterol acyltransferase), and TGM2 (transglutaminase 2) were differentially expressed both in discovery and verification phase. In order to select the best combination of proteins for predicting adverse outcomes, three-fold cross validation (CV) with repetition of 100 times was performed. The multi-marker model with 3 biomarkers (SVEP1, LCAT, TGM2) had a high discriminatory power to distinguish between the two groups (the area under the receiver operating characteristic, AUROC ¼ 0.855, p<0.001). CONCLUSION: Our result indicates that increased expression of SVEP1, LCAT, and TGM2 in mid-trimester amniotic fluid may predict APOs in women with SLE. A large scale prospective study is warranted to verify this finding. OBJECTIVE: Our objective was to identify risk factors for maternal depression utilizing the Adverse Childhood Experience (ACE) Questionnaire. STUDY DESIGN: A retrospective chart review from January 2017 until July 2018 of women presenting for prenatal care at our institution. Patients were included that completed both the Edinburgh Postnatal Depression Scale (EPDS) and the ACE questionnaire during the perinatal period. Statistical analysis using Chi-square and twosample t-test was performed, and a P-value of 0.05 was utilized for clinical significance. RESULTS: 60 patients met inclusion criteria. The majority of patients were African American and the average age was 27. Twenty-two percent of patients screened positive for depression in the perinatal period, which is higher than the national average of 14%. Of those that screened positive for depression, 46% endorsed suicidal or homicidal ideation. 80% of patients that screened positive for depression had an adverse childhood experience. The ACE scores ranged from 0 to 8 (maximum score is 10). An ACE score of at least 2 was associated with developing depression in the perinatal period (P-value 0.004). CONCLUSION: The ACE questionnaire is a well-studied screening tool that assesses a history of childhood neglect and abuse on the impact of chronic illness. To our knowledge, it has not been utilized during pregnancy until now. Based on our results, the ACE questionnaire is a tool that can be used to determine individuals at risk of developing perinatal depression. By screening patients earlier for depression utilizing a validated screening tool such as the EPDS, treatment can be initiated sooner, especially in a high risk low socioeconomic patient population where loss to follow up rates are high.
OBJECTIVE: Our objective was to identify risk factors for maternal depression utilizing the Adverse Childhood Experience (ACE) Questionnaire. STUDY DESIGN: A retrospective chart review from January 2017 until July 2018 of women presenting for prenatal care at our institution. Patients were included that completed both the Edinburgh Postnatal Depression Scale (EPDS) and the ACE questionnaire during the perinatal period. Statistical analysis using Chi-square and twosample t-test was performed, and a P-value of 0.05 was utilized for clinical significance. RESULTS: 60 patients met inclusion criteria. The majority of patients were African American and the average age was 27. Twenty-two percent of patients screened positive for depression in the perinatal period, which is higher than the national average of 14%. Of those that screened positive for depression, 46% endorsed suicidal or homicidal ideation. 80% of patients that screened positive for depression had an adverse childhood experience. The ACE scores ranged from 0 to 8 (maximum score is 10). An ACE score of at least 2 was associated with developing depression in the perinatal period (P-value 0.004). CONCLUSION: The ACE questionnaire is a well-studied screening tool that assesses a history of childhood neglect and abuse on the impact of chronic illness. To our knowledge, it has not been utilized during pregnancy until now. Based on our results, the ACE questionnaire is a tool that can be used to determine individuals at risk of developing perinatal depression. By screening patients earlier for depression utilizing a validated screening tool such as the EPDS, treatment can be initiated sooner, especially in a high risk low socioeconomic patient population where loss to follow up rates are high.
859 Predicting venous thromboembolism in obese pregnant women in a national study OBJECTIVE: Venous thromboembolism (VTE) in pregnancy and postpartum is a leading cause of maternal morbidity and mortality in developed countries, where obesity is a known risk for this complication. Current guidelines vary in which patients qualify for VTE prophylaxis, precluding a uniform approach for management. The purpose of this study was to derive a risk prediction model for VTE in obese pregnant women. STUDY DESIGN: We performed a retrospective cohort analysis using the Consortium on Safe Labor (CSL) database. The CSL includes detailed information from the electronic medical record for >200,000 deliveries from 19 hospitals across the United States from 2002 through 2008. Women ages 16-45 who were pregnant with singletons and had an obese body mass index (BMI>30 kg/m 2 ) were included in our study population. Maternal characteristics and preexisting conditions as well as pregnancy-related conditions and complications were analyzed to identify differences between those had a VTE and those who did not. Multivariable logistic regression was used in order to identify predictors of VTE. RESULTS: Of the 83,500 women who met inclusion criteria, on average women were 27.8 AE 6.0 years old, 38.6 AE 2.21 weeks gestation, with BMI of 35.8 AE 5.45 kg/m 2 , and cesarean delivery incidence of 35.2%. The racial makeup of our cohort was 45.1% Caucasian, 27.2% African American and 20.2% Hispanic women. 109 women (0.13%) experienced a VTE event. Independent predictors of VTE in our final multivariable predictive model included: mode of delivery, BMI, pregestational diabetes, chronic heart disease, preeclampsia, blood transfusion (intrapartum or postpartum), prenatal history of thromboembolic disorder, and postpartum maternal length of stay (Table) . A receiver operating characteristic curve was developed to assess the model; area under the curve was 0.826 (Figure) . OBJECTIVE: Vascular assessment of the retinal choroidal layer of pregnant women's eyes may serve as a noninvasive surrogate measure of placental perfusion. Previous research has reported conflicting data about the changes in the choroidal layer in healthy pregnancies. Chronic systemic vascular diseases such as hypertension and diabetes have been associated with decreased subfoveal choroidal thickness (SFCT) in nonpregnant adults, but the effect of these conditions have not been reported in pregnant women. Thus, the purpose of our study was to examine the subfoveal choroidal thickness (SFCT) in pregnant women with preexisting vascular disease. STUDY DESIGN: This prospective study included 67 pregnant women in the third trimester with indications for antenatal testing (ANT). SFCT measurements were collected using the Heidelberg optical coherence tomography angiography machine and measured using Spectralis software. Multivariable linear regression analyses were performed to determine correlations between maternal disease and the choroidal thickness. RESULTS: 67 women had both eyes imaged for a total of 134 SFCT values. 13% had chronic hypertension (CHTN), 9% had gestational hypertension (GHTN), 21% had gestational diabetes (GDM), 4% had type 2 diabetes mellitus (T2DM), and 54% were of advanced maternal age (AMA).
In this study cohort, pregnant women with CHTN or T2DM or both had significantly decreased mean SFCT (209um vs 245um, p¼0.008). However, having GDM or GHTN was not significantly correlated with decreased SFCT. Additionally, in a population of AMA patients, having any chronic disease was significantly negatively correlated with decreased mean SFCT values (199um vs 251um, p¼0.0003). CONCLUSION: In this study we found a significant association between chronic vascular disease and decreased SFCT in pregnant women. This same result was not seen for vascular disease with new onset in pregnancy, regardless of maternal age. Future studies are planned to determine whether decreased SFCT, presumably caused by arteriolar sclerosis, can be used as a biomarker to predict adverse pregnancy outcomes associated with ischemic placental disease.
861 The effects of Body Mass Index on pregnancy outcomes: a systematic review and meta-analysis 
OBJECTIVE:
To determine the effect of body mass index (BMI) on pregnancy outcomes STUDY DESIGN: We searched Medline, Embase, PubMed, www. clinicaltrials.gov and the Cochrane databases from inception until June 2017 for all experimental and observational studies reporting on pregnancy outcomes in women with BMI >30 using appropriate MeSH terms and keywords. Title/abstract screening and data extraction was performed in duplicate. As all identified studies were observational, risk of bias assessment was performed using the Newcastle Ottawa Scale for observational studies. Random-effects meta-analysis was used to calculate incidences and 95% confidence intervals (CI) for maternal and fetal/neonatal outcomes, stratified by BMI category. Relative risks (RR) for each outcome were similarly calculated over those for women with normal BMI. RESULTS: 5328 studies were identified, of which 19 representing 1,499,238 women were included in the descriptive analysis and 16 in the meta-analysis. All studies had a low risk of bias. Almost all maternal and fetal complications increased with each BMI class. The pregnancy risks with BMI>40 over those of normal BMI were as follows: hypertensive disorders of pregnancy (16.1% vs. 2.8%, RR 5.8 (4.4, 7.8)], gestational diabetes [16.4% vs. 3.6%, RR 4.6 (3.5, 5.9)], caesarean delivery [42.6% vs. 19.3%, RR 1.9 (1.6, 2.2)], maternal fever [2.7% vs. 2%, RR 1.3 (1.0, 1.6)], neonatal hypoglycemia (5.9% vs. 1.9%, RR 3.2 (2.7, 3.9)], macrosomia [12.8% vs. 5.2%, RR 3 (1.3, 6.9)], early neonatal infection [1.3% vs. 0.9%, RR 2.3 (1.6, 3.3)], Apgar<7 at 5 minutes [3.4% vs. 1.6%, RR 2 (1.4, 2.9)], neonatal intensive care unit admissions [9.2% vs. 4.7%, RR 1.7 (1.6, 2.0)], stillbirth [5.5/1000 vs, 3.6/1000, RR 1.6 (1.0, 2.6)], preterm birth [9.7% vs. 8.3%, RR 1.3 (1.2, 1.5)] and neonatal mortality (1.3% vs. 0.7%, RR 1.9 (1.3, 2.8)]. CONCLUSION: Although the increased pregnancy risks of raised BMI are known, this is the first study to systematically estimate the risks with each BMI category to inform practice and guide counselling.
